Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.

Combined chemo-/immunotherapy has shown high objective response rates and a significant though small proportion of long-term complete responders in metastatic malignant melanoma. The purpose of this study was to determine response rates, freedom from treatment failure (FFTF) and overall survival in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hoffmann, R., Müller, I., Neuber, K., Lassmann, S., Buer, J., Probst, M., Oevermann, K., Franzke, A., Kirchner, H., Ganser, A., Atzpodien, J.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group|1 1998
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2063152/
https://ncbi.nlm.nih.gov/pubmed/9792153
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados